Flexion Therapeutics, Inc. (NASDAQ:FLXN) last session’s volume of 0.76 million shares was higher than its average volume of 0.72 million shares. The stock, after opening at $17.66, hit $17.44 through the close by scoring 0.17%.Flexion Therapeutics, Inc. (FLXN) Analyst Opinion
Flexion Therapeutics, Inc. has a consensus outperform rating from 8 Wall Street analysts, and the number of shares currently sold short amount to at least 5.64% of shares outstanding. The stock sank -35.31% last month and is down -8.31 this year. Wall Street is only getting more bullish on the stock, with 8 of analysts who cover FLXN having a buy-equivalent rating. Analysts have placed a $36.38 price target on Flexion Therapeutics, Inc., suggesting a 108.6% gain from recent close. It’s currently trading about -40.7% below its 52-week high.Flexion Therapeutics, Inc. (NASDAQ:FLXN) Intraday View
This stock (FLXN) is ahead of its 52-week low with 84.55%. Its last month’s stock price volatility remained 4.97% which for the week stands at 5.09%. The share price has moved backward from its 20 days moving average, trading at a distance of -16.16% and stays -24.51% away from its 50 days moving average. Over the last five days, shares have faced -10.43% losses and now is down -11.8% since hitting its 200-day moving average of $20.53. Flexion Therapeutics, Inc. (FLXN) has made its way to a 12-month gain of 70.31%.
Turning to Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), its shares were trading at $11.27 a gain of $0.49, on the trading floor. The stock, after opening at $10.79, touched a high of $11.48 before paring much of its gains. So far, analysts are sticking with their neutral recommendations with the consensus call at 2. Corvus Pharmaceuticals, Inc. has 2 buy ratings, 0 holds and 0 sells even after the stock tumbled -49.09% from its high of $22.14 to a $223.26 million market value through last close.Corvus Pharmaceuticals, Inc. (CRVS) Consensus Price Target
The company’s consensus rating on Reuter’s scale improved from 1.6 to 2 during a month. Analysts set a 12-month price target of $21.25 a share. The target implies a 88.55% spike from where the shares are currently trading. Also, the current price highlights a discount of 130.7% to analysts’ high consensus price target.Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Intraday Trading
The counter witnessed a trading volume of 0.17 million shares versus an average volume of 0.23 million shares during last trading session. Its last month’s stock price volatility remained 5.42% which for the week approaches 5.19%. The lowest price the stock reached in the last trading day was $10.71 and compares with the $8.27 52-week low. The stock recovered 36.28% since its low point and has performed -21.19% year-to-date.